Skip to main content

Beta Cell Therapy in Diabetes

Objective

Type 1 diabetes is a serious chronic disease with major health risks and heavy burden on patients and society. It is caused by massive immune-mediated loss of insulin-producing beta cells in the pancreas that can so far not be locally corrected. A cellular allotransplant in the liver can install a new beta cell mass but the size is insufficient and the procedure faces limitations of donor shortage, inaccessibility of the implants, risks of associated immunosuppression. Our consortium of research, clinical and bioindustry teams is focused on overcoming these obstacles and implementing a roadmap for translation to preclinical models and clinical trials. We will pursue three interacting tracks. First, our ability to induce beta cell progenitors and stimulate beta cell proliferation in vivo should lead us to cells and compounds that activate this process in a diabetic pancreas, thus activating endogenous beta cell regeneration. Second, we will produce human beta (progenitor) cells in vitro by derivation from stem cells as well as from reprogrammed autologous cells; their therapeutic potential will be compared to that of primary human beta cells following implantation in rodents using a site that is accessible to modulation and monitoring. Third, we will design an antibody-based therapy for inducing immune tolerance to regenerated beta cells and to a beta cell implant. Efficacy, safety and regulatory criteria will be determined for clinical implementation. Clinical protocols will be prepared by adjusting associated therapy and by adopting an accessible and controlled implant site. Clinical trials will benefit from state-of-the art biologic markers for comparative analysis of the developed forms of beta cell therapy. This program should provide proof of principle for strategies that make beta cell transplantation and beta cell regeneration realistic for large numbers of type 1 diabetic patients, and probably also for some categories of type 2 diabetes.

Field of science

  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /medical and health sciences/clinical medicine/transplantation
  • /medical and health sciences/clinical medicine/endocrinology/diabetes
  • /medical and health sciences/medical biotechnology/medical bioproducts/implants

Call for proposal

FP7-HEALTH-2009-single-stage
See other projects for this call

Funding Scheme

CP-IP - Large-scale integrating project

Coordinator

VRIJE UNIVERSITEIT BRUSSEL
Address
Pleinlaan 2
1050 Brussel
Belgium
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 3 614 000
Administrative Contact
Christel Hendrieckx (Prof.)

Participants (17)

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 914 000
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Keith Cann (Mr.)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU contribution
€ 402 000
Address
Wellington Square University Offices
OX1 2JD Oxford
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Herman Waldmann (Prof.)
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 402 000
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Bart O. Roep (Prof.)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 500 000
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations
Administrative Contact
Annick Bertault (Ms.)
UNIVERSITE DE LILLE II - DROIT ET SANTE
France
EU contribution
€ 402 000
Address
Rue Paul Duez 42
59800 Lille
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Marie Gompel (Dr.)
THE HEBREW UNIVERSITY OF JERUSALEM
Israel
EU contribution
€ 502 000
Address
Edmond J Safra Campus Givat Ram
91904 Jerusalem
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Eran Vardi (Dr.)
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Switzerland
EU contribution
€ 402 000
Address
Batiment Ce 3316 Station 1
1015 Lausanne
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Emmanuelle Savioz-Dayer (Ms.)
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
EU contribution
€ 402 000
Address
Oude Markt 13
3000 Leuven
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Maria Vereeken (Ms.)
FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR
Italy
Address
Via Olgettina 60
20132 Milano
Activity type
Research Organisations
Administrative Contact
Mario Valsecchi (Mr.)
REGION HOVEDSTADEN
Denmark
EU contribution
€ 200 000
Address
Kongens Vaenge 2
3400 Hillerod
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Horst Donnerstag (Mr.)
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
France
EU contribution
€ 360 000
Address
Rue Michel Ange 3
75794 Paris
Activity type
Research Organisations
Administrative Contact
Liliane Flabbée (Ms.)
BETA-CELL
Belgium
EU contribution
€ 756 000
Address
Researchpark Z.1. 310
1731 Zellik
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Sven Andréasson (Mr.)
SARL ENDOCELLS
France
EU contribution
€ 403 000
Address
Boulevard Saint Germain
75007 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Anne-Fabienne Weitsch (Dr.)
CENTER FOR BETA CELL THERAPY IN DIABETES
Belgium
EU contribution
€ 1 205 000
Address
Laarbeeklaan 103
1090 Brussel
Activity type
Other
Administrative Contact
Christel Hendrieckx (Dr.)
NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU
Norway
EU contribution
€ 180 000
Address
Hogskoleringen 1
7491 Trondheim
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Wenche Lindseth (Ms.)
VIACYTE, INC CORPORATION
United States
EU contribution
€ 756 000
Address
General Atomics Court 3550
92121 San Diego Ca
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Anne Sandan (Ms.)
FONDAZIONE CENTRO SAN RAFFAELE
Italy
EU contribution
€ 300 000
Address
Via Olgettina 60
20132 Milano
Activity type
Research Organisations
Administrative Contact
Maria Rosa Pedrazzi (Dr.)